What changed
FDA approved Foundayo, orforglipron, for the stated weight-management indication. It is an oral non-peptide GLP-1 agonist.
What the evidence does not settle
GLP-1 names a receptor pathway, not a molecular peptide classification. Approval remains label-specific.
Evidence record
Event date: 2026-04-01. Source review: inherited source synthesis; not re-audited in this expansion. Editorial publication: 2026-10-29. Original source links below retain their publication dates. These dates are not interchangeable. This is targeted source synthesis, not an exhaustive archive or a qualified clinical/legal review.
Revision history
29 October 2026: migrated from the research edition, retaining source links and evidence qualifications; not re-audited in the current expansion. Report a proposed correction through Contact us; do not include patient data.